Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAKTIC
NCT03959891Phase 1Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- May 2019
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 1, open-label trial of ipatasertib in breast cancer (3 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 2 years. Started May 2019; status: active, not recruiting.
02
Drugs
ipatasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03959891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03959891.